AndrewRRezvaniMD

Oncology • Stanford, CA

Hematologic Oncology

Associate Professor of Medicine, Stanford University

Join to view full profile

Dr. Rezvani is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

See Dr. Rezvani's full profile

Already have an account?

Office
300 Pasteur Dr
Stanford, CA 94305
Phone+1 650-723-4000

Summary

I am a physician and clinical researcher at Stanford University, specializing in hematopoietic cell transplantation and cellular therapy.

Education & Training

University of WashingtonFellowship, Hematology and Medical Oncology, 2005 - 2007
University of WashingtonFellowship, Hematology and Medical Oncology, 2005 - 2006
Duke University HospitalResidency, Internal Medicine, 2001 - 2004
Lewis Katz School of Medicine at Temple UniversityClass of 2001

Certifications & Licensure

CA State Medical License 2014 - 2025
WA State Medical License 2004 - 2015
NC State Medical License 2001 - 2004
American Board of Internal Medicine Medical Oncology

Clinical Trials

Cyclophosphamide and Busulfan Followed by Donor Stem Cell Transplant in Treating Patients With Myelofibrosis, Acute Myeloid Leukemia, or Myelodysplastic Syndrome Start of enrollment: 2006 Dec 01
Completed
Not Applicable
Rituximab in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant for Relapsed or Refractory B-cell Lymphoma Start of enrollment: 2009 Feb 01
Completed
Phase 2
Donor Atorvastatin Treatment for Preventing Severe Acute Graft-Versus-Host Disease in Patients Undergoing Myeloablative Peripheral Blood Stem Cell Transplantation Start of enrollment: 2012 May 01
Completed
Phase 2
Fructooligosaccharides in Treating Patients With Blood Cancer Undergoing Donor Stem Cell Transplant Start of enrollment: 2016 Jun 01
Completed
Phase 1
Ibrutinib in Preventing Acute Leukemia in Patients After Reduced-Intensity Conditioning and Stem Cell Transplant Start of enrollment: 2017 Sep 12
Completed
Phase 2
Safety of Myeloablative Conditioning, Orca-T, and Allogeneic, Donor-Derived CD19/CD22-CAR (Chimeric Antigen Receptor) T Cells in Adults With B-cell Acute Lymphoblastic Leukemia (ALL) Start of enrollment: 2022 Aug 18
Recruiting
Phase 1
Evaluate Safety of Axicabtagene Ciloleucel Reinfusion (Axi-Cel-2) in Patients With Relapsed and/or Refractory Second Line High-Risk Non-Hodgkin Lymphoma After Standard of Care Axi-Cel Start of enrollment: 2023 May 23
Recruiting
Phase 1
Safety Study of Unlicensed IND Cord Blood Units Manufactured by the National Cord Blood Program for Unrelated Transplantation Start of enrollment: 2012 Feb 01
Recruiting
Phase 2
A Multicenter Access and Distribution Protocol for Unlicensed Cryopreserved Cord Blood Units (CBUs) Start of enrollment: 2011 Oct 01
Recruiting
Join now to see all

Publications & Presentations

PubMed

Exploring facilitators and barriers to daily chlorhexidine gluconate bathing in adult patients undergoing hematopoietic stem cell transplantation.
Ashley L Artese, Michele Sainvil, Laura J Fish, Lauren Hill, Tamara Somers
Supportive Care in Cancer. 2024-11-28
Belumosudil combination therapy for chronic graft-versus-host-disease in real-world clinical practice.
Michelle M Chin, John S Tamaresis, Laura J Johnston, Robert Lowsky, Everett Meyer
Bone Marrow Transplantation. 2024-11-18
3 citations
A phase 1 clinical trial of NKTR-255 with CD19-22 CAR T-cell therapy for refractory B-cell acute lymphoblastic leukemia.
Hrishikesh Srinagesh, Clayton Jackson, Parveen Shiraz, Nikeshan Jeyakumar, Mark Hamilton
Blood. 2024-10-17

Abstracts/Posters

Improved Outcomes for Relapsed/Refractory Classic Hodgkin Lymphoma Following Autologous Stem Cell Transplantation in the Era of Novel Agents
Andrew R Rezvani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
No Engraftment Advantage after Single or Double Umbilical Cord Blood Transplant (CBT) with the Addition of a Non-HLA Matched Off-the-Shelf Expanded Cord Blood Unit Com...
Andrew R Rezvani, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019

Press Mentions

Study Predicts Who May Benefit from CAR-T Cell Therapy for Blood CancersAugust 2nd, 2021
Nevada Cancer Survivor Found to Have Two Different Sets of DNA After Bone Marrow Transplant 4 Years AgoDecember 10th, 2019
After Bone Marrow Transplant, Patient's Blood Contains Only Donor's DNA: Three Months After a Nevada Man Received a Bone Marrow Transplant, Tests Revealed the DNA in His Blood Had Been Replaced by the DNA of His Donor, a Man He Barely Knew, According t...December 9th, 2019